TD Cowen analyst Marc Frahm has maintained their bullish stance on CRDF stock, giving a Buy rating today.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Marc Frahm has given his Buy rating due to a combination of factors related to Cardiff Oncology’s recent developments and future prospects. The company reported a manageable net loss for Q3:25 and has a sufficient cash reserve to fund operations into Q1:27, which provides a stable financial outlook. Additionally, Cardiff’s primary asset, onvansertib, has shown promising results in a Phase II trial for metastatic colorectal cancer, demonstrating a significant objective response rate benefit.
The ongoing trial and the anticipated release of updated data in Q1:26, including mature progression-free survival data, are key factors in the positive outlook. Furthermore, Cardiff’s management is planning a Phase III trial with the intent to seek accelerated approval, drawing on successful precedents set by other companies. This strategic approach, combined with the potential regulatory updates, supports the Buy rating as it indicates a clear path toward potential market approval and growth.